SCHEMBL4378957

SCHEMBL4378957

COc1cc2c(Oc3ccc4ccccc4n3)ncnc2cc1OCCCN1CCOCC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 11/20 0.61
KDR P35968 9/20 0.57
FLT4 P35916 3/20 0.56
AURKA O14965 3/20 0.56
AURKB Q96GD4 3/20 0.56
PDGFRB P09619 2/20 0.56
TEK Q02763 2/20 0.56
EGFR P00533 6/20 0.55
ATM Q13315 1/20 0.54
FGFR1 P11362 1/20 0.54
FLT1 P17948 1/20 0.54
KDM1A O60341 1/20 0.53
ROCK2 O75116 1/20 0.53
ALDH1A1 P00352 1/20 0.53
LCK P06239 1/20 0.53
FYN P06241 1/20 0.53
RET P07949 1/20 0.53
MET P08581 1/20 0.53
MAPT P10636 1/20 0.53
PDGFRA P16234 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4376854 0.88 SRC (0.65) SRCKDREGFRATMKDM1A
SCHEMBL4023679 0.86 SRC (0.66) SRCKDRFLT4AURKAAURKB
SCHEMBL17278101 0.86 SRC (0.66) SRCKDRFLT4AURKAAURKB
SCHEMBL4379508 0.85 SRC (0.58) SRCKDRFLT4AURKAAURKB
SCHEMBL4382624 0.82 SRC (0.61) SRCKDREGFRATM
SCHEMBL5565918 0.82 SRC (0.57) SRCKDRFLT4AURKAAURKB
SCHEMBL4383316 0.82 SRC (0.58) SRCKDRFLT4AURKAAURKB
Hydrochloric Acid SCHEMBL5566627 0.82 SRC (0.56) SRCKDRFLT4AURKAAURKB
SCHEMBL7209612 0.82 EGFR (0.62) SRCKDRFLT4AURKAAURKB
SCHEMBL5564985 0.81 SRC (0.55) SRCKDRFLT4AURKAAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8492560-B2 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2013-07-23 US disclosed
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors STOKES ELAINE S E (GB) 2012-08-02 US disclosed
EP-2050744-A1 Quinazoline derivatives as angiogenesis inhibitors AstraZeneca AB (SE) 2009-04-22 EP disclosed
US-7074800-B1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB (SE) 2006-07-11 US disclosed
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors ASTRAZENECA AB 2006-01-05 US disclosed
EP-1553097-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AND INTERMEDIATES THEREFORE AstraZeneca AB (SE) 2005-07-13 EP disclosed
EP-1154774-B1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2005-06-22 EP disclosed
EP-1154774-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS AstraZeneca AB (SE) 2001-11-21 EP disclosed
WO-2000047212-A1 QUINAZOLINE DERIVATIVES AS ANGIOGENESIS INHIBITORS ASTRAZENECA AB (SE) 2000-08-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120197027-A1 Quinazoline Derivatives as Angiogenesis Inhibitors VEGFA, FLT1, KDR SRC 1517/4885KDR 3/4885FLT4 4/4885
US-20060004017-A1 Quinazoline derivatives as angiogenesis inhibitors FLT4, NOS3, FLT1 SRC 1276/4885KDR 4/4885FLT4 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.